Dravet syndrome
Drug research and approvals for dravet syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 14 studies of dravet syndrome are recruiting on ClinicalTrials.gov, Health Canada has authorized 12 drug trials for it since 2013, FDA has 8 approved and 17 open orphan designations naming it, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 14
- Trials authorized in Canada: 12
- FDA orphan approvals: 8
- EU medicines: 2
- A Study to Evaluate the Safety and Pharmacokinetics of RC001 in Children With Dravet SyndromeNCT07675746 · Early Phase 1 · Second Affiliated Hospital of Guangzhou Medical University · starts Dec 22, 2025
- ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet SyndromeNCT07531745 · Phase 1 / Phase 2 · Ionis Pharmaceuticals, Inc. · starts May 21, 2026
- Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene MutationNCT07251673 · Not reported · Assistance Publique - Hôpitaux de Paris · starts Sep 15, 2025
- The FINTEPLA as an Anti-SUDEP Therapy in Dravet Syndrome ProjectNCT07112365 · Phase 4 · The University of Texas Health Science Center, Houston · starts Apr 27, 2026
- A PET-MRI Study of Serotoninergic Brainstem Pathway in Patients With Dravet SyndromeNCT07013331 · Not applicable · Hospices Civils de Lyon · starts May 4, 2026
- Registry and Natural History of Epilepsy-Dyskinesia SyndromesNCT06967727 · Not reported · Boston Children's Hospital · starts Jun 1, 2025
- Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of AgeNCT06598449 · Phase 4 · University of Colorado, Denver · starts Oct 22, 2024
- A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of…NCT06585605 · Not reported · Boston Children's Hospital · starts Jul 1, 2024
- BMB-101 in Absence Epilepsy and DEENCT06401538 · Phase 2 · Bright Minds Biosciences Pty Ltd · starts Dec 5, 2024
| Oct 28, 2026 | Endeavor: a clinical study to evaluate the safety and efficacy of ETX101, an AAV9-delivered gene therapy in infants and children with SCN1A-positive Dravet…ETX101 | Encoded Therapeutics, Inc. | Pending |
| Mar 4, 2026 | Phase 1-2, open-label, single and multiple ascending dose study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of…ION337 | Ionis Pharmaceuticals | Ongoing |
| Jan 30, 2025 | A phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of…Bexicaserin (LP352) | Longboard Pharmaceuticals | Ongoing |
| May 25, 2022 | Fenfluramine for the treatment of refractory epilepsy in adult Dravet patientsFenfluramine | University Health Network | Pending |
| Mar 22, 2022 | A phase 3, prospective, open-label, multisite, extension of phase 3 studies to assess the long-term safety and tolerability of soticlestat as adjunctive…Soticlestat (TAK-935) | Takeda Pharmaceuticals USA | Closed |
| Jul 30, 2021 | A 20-week multicenter, randomized, double-blind, placebo-controlled trial of EPX-100 (clemizole hydrochloride) as adjunctive therapy in children and adult…Clemizole (EPX-100) | Epygenix Therapeutics, Inc. | Ongoing |
| Jul 29, 2021 | A multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety, and tolerability of soticlestat as…Soticlestat (TAK-935) | Takeda Pharmaceuticals USA | Closed |
| May 13, 2021 | Extended access program and retrospective chart review for lorcaserin in Dravet syndrome and other refractory epilepsiesLorcaserin | Eisai | Closed |
| Dec 22, 2020 | A multicenter, double-blind, randomized, placebo-controlled, parallel-group study with open-label extension phase of lorcaserin as adjunctive treatment in…Lorcaserin | Eisai | Closed |
| Nov 20, 2019 | An open-label extension trial to assess the long-term safety of ZX008 (fenfluramine hydrochloride) oral solution as an adjunctive therapy for seizures in…Fenfluramine (ZX008) | Zogenix International Limited | Closed |
| Jul 14, 2022 | DiacomitTreatment of seizures associated with Dravet syndrome (DS) in patients taking clobazam who are 6 months of age and older and weighing 7 kg… | Biocodex | Approved |
| Jul 31, 2020 | EpidiolexTreatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients… | Jazz Pharmaceuticals Research UK Limited | Approved |
| Jul 31, 2020 | EpidiolexTreatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex (TSC) in patients 1 year of… | Jazz Pharmaceuticals Research UK Limited | Approved |
| Jul 31, 2020 | EpidiolexTreatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients… | Jazz Pharmaceuticals Research UK Limited | Approved |
| Jun 25, 2020 | FinteplaFintepla (fenfluramine) is indicated for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older. | UCB, Inc. | Approved |
| Sep 28, 2018 | EpidiolexEPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients 2… | Jazz Pharmaceuticals Research UK Limited | Approved |
| Sep 28, 2018 | EpidiolexEPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients 2… | Jazz Pharmaceuticals Research UK Limited | Approved |
| Aug 20, 2018 | DiacomitDIACOMIT is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients 2 years of age and older taking… | Biocodex | Approved |
| Oct 22, 2026 | 15-base residue modified antisense oligonucleotide (ASO)…Treatment of Dravet syndrome | Ionis Pharmaceuticals | Designated |
| Apr 16, 2025 | Chemically modified oligonucleotide designed as an…Treatment of Dravet syndrome | RecoRNA (Guangzhou) Biotechnology Co., Ltd. | Designated |
| Jan 16, 2025 | (R)-N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamideTreatment of Dravet syndrome | iQure Pharma Inc | Designated |
| Sep 17, 2024 | Bexicaserin hydrochloride (bexicaserin)Treatment of Dravet syndrome | Longboard Pharmaceuticals, Inc. | Designated |
| Jul 27, 2022 | Small molecule agonist of 5-hydroxytryptamine serotonergic…Treatment of Dravet Syndrome | Xenon Pharmaceuticals Inc. | Designated |
| Oct 12, 2021 | 2-[(3-Methylbutyl)amino]-1,4-naphthalenedioneTreatment of Dravet Syndrome | Neuroene Therapeutics | Designated |
| Aug 31, 2020 | LorcaserinTreatment of Dravet syndrome | Eisai Inc. | Designated |
| Dec 18, 2020 | FinteplaFenfluramine · orphan | UCB Pharma S.A. | EMA ↗ |
| Sep 19, 2019 | EpidyolexCannabidiol · orphan | Jazz Pharmaceuticals Ireland Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA